This is a typical Abbott play. Will buy St Jude combine their stent business into the St Jude business and spin out as a separate entity and take a nice profit. The separate businesses lack the brevity in their respective portfolios to real competitors when there is a lack of real differentiation in stents, pacers, and EP equipment. Same way they bought Knoll Pharma, Solvay and then split off Abbvie.
From an AHZ viewpoint there's nothing really to see here. In saying that I encourage Miles White to consider perhaps sending some Abbott money our way.
This is a typical Abbott play. Will buy St Jude combine their...
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.15 |
Change
0.350(2.97%) |
Mkt cap ! $256.8M | |||
| Open | High | Low | Value | Volume |
| $11.80 | $12.15 | $11.21 | $376.0K | 32.22K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 139 | $12.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.15 | 830 | 1 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |